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Uptake of rat and human cc,-macroglobulin-trypsin complexes was measured in rat hepatocytes, rat and 
human adipocytes and human fibroblasts. Uptake and degradation of 1251-labelled ratcomplex were about 
one-third of that of the human complex in the various isolated cell types. In rat hepatocytes, the apparent 
K,,, for cell association of the rat complex was about 16 nM as compared to about 6 nM for the human 
complex. The V,,, values were similar, about 1 x lo4 molecules cell-l min-1. Thus, rat cr,-macroglobulin 
(an acute-phase protein) complexed with trypsin follows the same pathways of uptake as the human homo- 
logue, although with a somewhat lower affinity for the uptake system. 
urMacroglobulin Adipocyte Hepatocyte Species difference 
1. INTRODUCTION 
Recent studies have shown that human 
cY*-macroglobulin-trypsin complex is specifically 
associated to and degraded by isolated rat 
hepatocytes [l]. Most of the cell-associated 
material is internalised at 37°C [l] and we 
therefore refer to cell association as uptake. Other 
studies showed that the rapid removal of human 
az-macroglobulin-trypsin from the circulation in 
rats [2] and mice [3] is mainly accounted for by its 
uptake into hepatocytes. However, rat plasma con- 
tains 2 macroglobulins which are homologous to 
human cuz-macroglobulin. One of them, rat 
at-macroglobulin, is structurally quite different 
from human crz-macroglobulin [4]. The concentra- 
tion of this homologue in rat plasma is high 
(2-4 mg/ml) and relatively constant, and in this 
sense it resembles human az-macroglobulin. Rat 
a*-macroglobulin is structurally and serologically 
similar to human cYz-macroglobulin. However, its 
concentration in plasma of adult rats is normally 
low (15-30 ,ug/ml) and may increase to 
2-4 mg/ml during acute inflammation [5,6]. In 
this sense it is different from human 
a*-macroglobulin which is not an acute-phase pro- 
tein. We decided to compare cell association and 
degradation of rat and human cyz-macroglobulin in 
different cell types from rats and humans since the 
physiology of the macroglobulins seems quite dif- 
ferent in the 2 species and since the rat is a com- 
monly used laboratory animal. 
2. MATERIALS AND METHODS 
Trypsin (60% active) was from Boehringer; soy- 
bean trypsin inhibitor and bovine serum albumin 
(fraction V) were from Sigma. Colla:;:ase (type 1) 
was from Worthington and I (about 
2 Ci/pmol) from Amersham International, 
England. Male rats (about 250 g) received sub- 
cutaneous injections of 0.5 ml croton oil in the 
subscapular area and blood was collected after 
48 h. cuz-Macroglobulin was prepared from rat or 
human plasma by Zn2+ chelate chromatography 
and Sephacryl S300 gel chromatography according 
to NelIes and Schnebli [7] as described [8]. Alter- 
natively, rat cuz-macroglobulin was prepared in the 
following way. EDTA plasma (100 ml) from rats 
with adjuvant-induced arthritis was mixed with 
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5 mM benzamidine and 2 mM phenylmethanesul- 
fonyl fluoride. Globulins were fractionally pre- 
cipitated at 0°C with 6-14% polyethylene glycol 
4000 and redissolved in 0.02 M Tris-HCl, pH 7.4. 
mz-Macroglobulin was then purified by sequential 
chromatography on the following columns: (1) 
Fractogel TSK DEAE-650M (Merck, Darmstadt) 
(3.2 x 27 cm) using 0.02 M Tris-chloride, pH 7.4, 
and a 600 ml gradient of O-O.5 M NaCl; (2) Frac- 
togel TSK HW-55F (Merck) (3.2 x 80 cm) using 
Tris-chloride, pH 7.8, and 0.15 M NaCl; (3) zinc 
chelated to immobilized iminodiacetic acid on 
Fractogel TSK (Pierce, Rockford, IL) (1.5 x 
15 cm) loading in Tris-chloride, pH 7.8, and 
eluting with 0.05 M sodium phosphate, pH 6.0, in 
0.15 M NaCl [8]; (4) Mono Q (Pharmacia, Upp- 
sala) with 0.05 M Tris, pH 7.8, and 0.1-0.4 M 
NaCl. This preparation was obtained through the 
courtesy of Drs K. Lonberg-Holm and D.L. Reed, 
DuPont, Central Research Station, Wilmington, 
DE, and the method will be described in detail 
elsewhere. 
The cuz-macroglobulins were iodinated and com- 
plexed with trypsin as described [l] except that 
0.5 mol iodine was used per mol protein. The con- 
centrations were determined using E&$Y = 8.9. All 
treatments of human and rat az-macroglobulin 
were carried out in parallel. After complexing with 
trypsin the 2 preparations of rat cuz-macroglobulin 
were compared in several experiments and no dif- 
ference was found in their ability to compete with 
uptake of ‘251-labelled human complex (cf. fig. 1). 
1251-labelled rat cuz-macroglobulin-trypsin was 
injected intravenously into anesthetized 200 g rats 
and the cellular localization of the radioactivity 
was determined using light microscopic auto- 
radiography as in [2]. Rat hepatocytes were 
prepared by in vitro perfusion of the liver from 
animals weighing 190-230 g with collagenase 
[1,9]. Aliquots of cell suspension (0.5 ml with 2 x 
lo5 cells/ml unless otherwise stated) were in- 
cubated in buffer (37”C, pH 7.6) containing 
Krebs’ salts, 10 mM Hepes and 5% (w/v) albumin. 
By the end of the incubation, 400 ~1 cell suspension 
was transferred to 550 ~1 microfuge tubes contain- 
ing 75 ~1 dibutylphthalate and centrifuged for 
1 min at 10000 x g. Finally, the tube was cut 
through the oil layer and the cell pellet counted 
[ 1, lo]. Rat [ 1,l l] and human [ 121 adipocytes were 
prepared and incubated (5 x lo5 cells/ml) follow- 
ing standard methods; Human fetal fibroblasts 
were maintained in Dulbecco’s modification of 
Eagle’s medium fortified with 2 mM L-glutamine, 
10% fetal calf serum, 50 mg/l neomycin, and 2.5 
x lo4 U/l nystatin and buffered with 20 mM 
Hepes. Two days before the experiment the cells 
were trypsinized, washed, filtered through a 56 pm 
nylon mesh and seeded in plates with a culture area 
of 4.5 cm2 [13]. On the day of the experiment the 
cells were washed and incubated in situ using the 
same buffer as for the other cell types. The incuba- 
tions were stopped by washing the cells 3 times 
with 1 ml ice-cold 0.9% NaCI. Finally, the cells 
were dissolved by treatment with 0.5 M NaOH at 
8O’C for 6 h and the cell-associated radioactivity 
determined. 
3. RESULTS 
The half time of disappearance of rat 
a2-macroglobulin-trypsin complex from the blood 
in anesthetized rats was about 4 min, which is 
twice that of the human complex [2] and uptake in- 
to the liver accounted for 80-90% of the clearance 
(not shown). Table 1 shows that the uptake was 
mainly into hepatocytes in agreement with 
previous data for human az-macroglobulin-trypsin 
PI. 
Fig.lA shows the effect of unlabelled rat and 
human cr2-macroglobulin-trypsin on the uptake of 
20 pM labelled human complex into isolated rat 
hepatocytes. Half-maximal inhibition was ob- 
Table 1 
Distribution of grains over liver tissue as analyzed by 
light microscopic autoradiography of tissue fixed 10 min 
after injection of about 50,&i ‘251-labelled rat 
a2-macroglobulin-trypsin 
Hepatocytes Non- Space of Disse 
hepatocytes and lumen of 
sinusoides 
Grains 1318 28 10 
Four sections from different parts of the liver were 
analyzed and 1356 grains were counted over 3.8 x 
104pm2 using a magnification of x 2048. The 
autoradiographic background was negligible, i.e. less 
than 50 grains/lo5 pm2 
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Fig.1. Inhibition of the uptake of ‘ZSl-labelled human al-macroglobulin-trypsin by unlabelled complexes in rat 
hepatocytes (A) and rat adipocytes (B). The cells were incubated for 3 h with 20 pM human complex in the absence 
or presence of unlabelled human (M) or rat (ti) complexes. The open symbols represent the equivalent data 
for the uncomplexed macroglobulin. The points represent the means of 3 replicates. The coefficient of variation was 
about 6%. The lines are calculated by linear regression on the points representing the straight part of the competition- 
inhibition curves. The radioactivity associated with the cells in the presence of 500 nM unlabelled human 
az-macroglobulin-trypsin was regarded as non-specific and the horizontal lines indicate half of the maximal specific cell 
association. 
tamed with 13.9 nM of the rat complex and 
5.1 nM of the human complex, yielding a relative 
potency of the rat complex of 37%. The mean 
relative potency of the rat complex was calculated 
from this and similar experiments as 32 + 5% (SD, 
n = 4). Fig.lA also shows the low potencies of the 
uncomplexed macroglobulins. Fig. 1B shows the 
equivalent data using rat adipocytes. The mean 
relative potency of rat cuz-macroglobulin-trypsin 
was 38 f 4% (SD, n = 4) in this system. 
Table 2 shows that the uptake of 20 pM (&Km) 
‘251-labelled rat a2-macroglobulin-trypsin is 
30-50% of that of the labelled human complex in 
the 4 cell types tested. Other experiments (not 
Table 2 
Specific uptake of 20 pM rat or human ‘251-labelled crz-macroglobulin-trypsin in rat 
and human cells 
Rat Rat Human Human 
hepatocytes adipocytes adipocytes fibroblasts 
Human cuz-macroglobulin- 
trypsin 4.5 f 0.3 4.0 & 0.3 0.9 + 0.1 5.6 + 0.2 
Rat cuz-macroglobulin- 
trypsin 2.0 +- 0.2 1.7 + 0.2 0.4 * 0.1 3.4 + 0.1 
Incubations were carried out for 3 h at 37°C and the percent of cell-associated 
radioactivity was determined. The results with the rat cells are the mean values of 4 
independent experiments f 1 SD. The results with the human cells are given as the 
mean of at least 4 replicate values f 1 SD, and this experiment was repeated with 
essentially identical results 
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shown) demonstrated that the degradation (forma- 
tion of products soluble in 12% trichloroacetic 
acid) of 1251-labelled rat tu2-macroglobulin-trypsin 
in suspensions of rat hepatocytes was about half of 
that of the human homologue. 
Fig.2 shows that the apparent affinity for uptake 
of the rat complex was about one-third of that for 
the human complex, whereas the maximal 
velocities were not significantly different. The K,,, 
values of 6 nM for the human complex and 16 nM 
for the rat complex are in agreement with the com- 
petition experiment shown in fig.lA. The I’,,, 
value of 16 pM . min-’ corresponds to a rate of up- 
take of 6 x lo3 molecules. cell-‘. min-‘. Three ad- 
ditional experiments gave similar Km values 
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Fig.2. Concentration dependence of uptake of rat 
(ti) and human (o---o) cu2-macroglobulin-trypsin 
complex in rat hepatocytes. The hepatocyte 
concentration was 1.2 x 106/ml and the incubation time 
was 40 min. The data are plotted according to Hanes’ 
modification of the Michaelis-Menten equation: 
S/v = I/ V,,,,, . S + K,,,/ V,,,ax 
using linear regression. The K,,, values were calculated 
from the negative intercepts with the abscissa as 6.0 nM 
for the human complex and 16.4 nM for the rat 
complex. The V max values were calculated from the 
reciprocal slopes as 15.3 pM.min-’ for the human 




Previous results have shown that human, rat and 
mouse a2-macroglobulin-trypsin complexes are 
removed from the blood by the same saturable 
pathway in mice [14]. This was thought to involve 
reticuloendothelial cells and mainly Kupffer cells 
[15,16]. The present results show that rat 
cuz-macroglobulin-trypsin, like the human complex 
[2], is mainly taken up by hepatocytes in the rat. 
However, the apparent affinity for uptake of the 
rat complex in these cells is only about one third of 
that of the human complex. The same applies to 
uptake in human fibroblasts and in adipocytes 
from both rats and humans. This moderate dif- 
ference in affinity may well be due to structur- 
al differences between the rat and human 
macroglobulins (cf. [17]). In any case, it seems ap- 
propriate, in view of the present results, to use 
human a2-macroglobulin complexes in studies 
employing the rat as the experimental animal. 
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